Carotid Intervention

Supplement

Transradial Coronary Artery Procedures: Tips for Success

Percutaneous revascularisation has become the cornerstone of ischaemic heart disease management.1,2 Historically, coronary angiography and intervention was predominantly performed via the common femoral artery.3 However, this procedure has an associated 1.5–9.0 % risk of complications, most of which are related to bleeding at the femoral access site.4 Despite a significant reduction in the incidence of major femoral bleeding complications during 1994 to 2005 from 8.4 % to 3.5 %, respectively,5 related to technological advancement

Use of Intravascular Ultrasound Imaging in Percutaneous Coronary Intervention to Treat Left Main Coronary Artery Disease

Detection of obstructive disease of the left main coronary artery (LMCA) is relatively unusual in the catheterisation laboratory, as it accounts for approximately 4 % of all coronary angiograms, with isolated LMCA disease observed in only 5–10 % of these cases.1

Use of Embolic Protection Devices in Peripheral Interventions

Catheter-based vascular interventions continue to evolve as new devices continue to expand the capabilities of interventionalists and improve patient safety. The importance of athero-embolisation during vascular intervention has long been recognised.1 Embolic protection devices (EPDs) were developed to help prevent embolisation during endovascular procedures.

AXXESS™ Stent: Delivery Indications and Outcomes

A bifurcation lesion within the coronary arterial circulation is defined as a stenosis occurring at, or adjacent to, a significant division of a major epicardial coronary artery.1 Bifurcation lesions account for 1–20 % of all percutaneous coronary interventions (PCIs), and treatment remain technically challenging despite advances in PCI techniques and third-generation drug-eluting stent (DES) technology.

Cre8™ Unique Technology in Challenging Daily Practice

The use of coronary artery stents was first described in 1986, and percutaneous coronary intervention (PCI) involving stenting is now routine practice. However the problem of restenosis, caused by neointimal tissue growth, led to the development of drug-eluting stents (DES), which allow controlled release of antiproliferative drugs at the arterial wall.1 The use of DES has significantly improved clinical outcomes compared to bare metal stents (BMS).2,3 But safety issues emerged with the use of DES.